- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- July 2024
- 70 Pages
Global
From €4200EUR$4,750USD£3,623GBP
- Report
- February 2025
- 218 Pages
Global
From €4243EUR$4,799USD£3,660GBP
- Report
- January 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- October 2024
- 200 Pages
Global
From €3316EUR$3,750USD£2,860GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2466EUR$2,789USD£2,127GBP
- Report
- March 2025
- 83 Pages
Global
From €3500EUR$4,240USD£3,125GBP
- Report
- June 2025
- 300 Pages
Europe
From €3421EUR$3,869USD£2,951GBP
- Report
- January 2023
- 127 Pages
Global
From €1989EUR$2,250USD£1,716GBP
- Report
- July 2024
- 150 Pages
Global
From €5261EUR$5,950USD£4,538GBP
- Report
- May 2021
- 50 Pages
China
From €2299EUR$2,600USD£1,983GBP
- Report
- May 2024
- 140 Pages
Global
From €5746EUR$6,499USD£4,957GBP
- Report
- June 2025
- 250 Pages
Canada
From €2466EUR$2,789USD£2,127GBP
- Report
- February 2024
- 70 Pages
Germany
From €4200EUR$4,750USD£3,623GBP
- Report
- February 2024
- 70 Pages
Italy
From €4200EUR$4,750USD£3,623GBP
- Report
- February 2024
- 70 Pages
Oman
From €4200EUR$4,750USD£3,623GBP
- Report
- February 2024
- 70 Pages
Egypt
From €4200EUR$4,750USD£3,623GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4200EUR$4,750USD£3,623GBP
- Report
- February 2024
- 70 Pages
France
From €4200EUR$4,750USD£3,623GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4200EUR$4,750USD£3,623GBP

Trulicity is a medication used to treat type 2 diabetes, a chronic endocrine and metabolic disorder. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to reduce blood sugar levels by stimulating the release of insulin from the pancreas. Trulicity is administered as a once-weekly subcutaneous injection and is available in both 0.75 mg and 1.5 mg doses. It is also used to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes and established cardiovascular disease.
Trulicity is part of a larger market of endocrine and metabolic disorder drugs, which includes other GLP-1 receptor agonists, such as Victoza and Bydureon, as well as insulin, sulfonylureas, and thiazolidinediones. These medications are used to treat a variety of endocrine and metabolic disorders, including diabetes, obesity, and thyroid disorders.
Some companies in the Trulicity market include Eli Lilly and Company, Novo Nordisk, Merck & Co., and Sanofi. Show Less Read more